Please assess the completion status of the following clinical trial:

Trial Title: DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a pathologically documented locally advanced or metastatic adenocarcinoma of gastric or gastroesophageal junction~2. Progression on and after at least 2 prior regimens~3. Has an adequate tumor sample~4. Has measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1~Exclusion Criteria:~1. Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia~2. Has a QTc prolongation to \> 450 millisecond (ms) in males and \> 470 ms in females~3. Has a medical history of clinically significant lung disease~4. Is suspected to have certain other protocol-defined diseases based on imaging at screening period~5. Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:~   1. safety or well-being of the participant or offspring~  2. safety of study staff~  3. analysis of results

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parallel: DS-8201a (Type: EXPERIMENTAL): Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
- Parallel: Physician's Choice (Type: ACTIVE_COMPARATOR): Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
- Exploratory: Naïve HER2 IHC 2+/ISH- (Type: OTHER): A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
- Exploratory: Naïve HER2 IHC 1+ (Type: OTHER): A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).